10-Q · May 12, 2026
GUTS reported a significant improvement in Q4 2026 compared to the same quarter last year, with net income of $9.2 million contrasting sharply to a loss of $23.7 million in Q4 2025. Revenue remained at zero,…
Earnings analysis · 10-Q
GUTS earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpt does not include the financial statements or MD&A needed to quantify Q2 revenue, margins, EPS, cash flow, balance-sheet changes, or segment performance, so those metrics are left null. The…
Read full summary
The provided 10-Q excerpt does not include the financial statements or MD&A needed to quantify Q2 revenue, margins, EPS, cash flow, balance-sheet changes, or segment performance, so those metrics are left null. The principal new disclosed risk is Nasdaq compliance: the stock must regain the $1.00 minimum bid requirement by September 9, 2026 after 30 consecutive business days below the threshold. Termination of the Sales Agreement effective April 6, 2026 may further constrain financing flexibility, despite management reporting effective controls as of June 30, 2026.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Controls remained effective
Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026. The company also reported no changes during the quarter ended June 30, 2026 that materially affected internal control over financial reporting.
-
No material legal proceedings
The company reported no material legal proceedings in the period covered by the filing.
What to watch
-
Nasdaq delisting risk escalated
Nasdaq notified the company on March 13, 2026 that its closing bid price had been below the $1.00 minimum for 30 consecutive business days. The company has until September 9, 2026 to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive trading days; failure could lead to delisting and impair access to equity financing.
-
Equity financing capacity reduced
The company terminated its Sales Agreement effective April 6, 2026. The filing does not quantify the resulting impact on liquidity or future capital-raising capacity, but the termination removes an identified equity financing mechanism.
Management's outlook
No quantitative revenue or EPS outlook is included in the provided 10-Q text; the excerpt does not provide an outlook, liquidity outlook, or capital-spending forecast.
Earlier filings 3
10-K · March 24, 2026
Fractyl Health positions itself as a developer of disease‑modifying therapies for obesity and type 2 diabetes focused on a gut‑targeting device (Revita) and a pancreatic gene therapy platform (Rejuva). The company…
10-Q · August 12, 2025
Fractyl reported no revenue for Q2 2025 and a larger loss versus the year-ago quarter: net loss was $(27,889) (three months) and $(51,624) (six months) with diluted EPS of $(0.57) for the quarter vs $(0.36) a year ago.…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.